Alpha-GPC

evidence score

nootropic

152 studies

L-alpha-glycerylphosphorylcholinecholine alfosceratealpha-glycerophosphocholine

Alpha-GPC is a choline-containing phospholipid that crosses the blood-brain barrier efficiently. It serves as a precursor to acetylcholine synthesis and has demonstrated cognitive-enhancing properties, particularly in aging populations. It also shows acute effects on growth hormone secretion and power output.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Feb 19, 2026

Dosing

Typical

600 mg

300 mgRange1200 mg

Frequencydaily

Set height & weight in Settings to see your dose.

Pharmacology

Half-life4-6 hours

Onset30-60 minutes

Duration4-6 hours

Routes

oral

Evidence Score

Level B — Moderate

152 studies indexed · 1 meta-analysis

Scoring Factors

Volume(40%)~44/100

Quality(30%)~45/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Alpha-GPC is currently categorized as a nootropic compound.

Evidence is moderate (68/100): promising signal from 152 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Rapidly absorbed choline donor; crosses BBB and upregulates acetylcholine synthesis in cortical neurons

Practical Context

Strongest current signals

Level B: Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double-blind, randomized, placebo-controlled trial.
Level C: Unlocking the potential of l-α-glycerylphosphorylcholine in the food industry: From safety approvals to market prospects.
Level C: Choline Alphoscerate: A Therapeutic Option for the Management of Subthreshold Depression in the Older Population.